Provision of Highest Quality Information
Safety Management and Regulatory Affairs System
Pharmaceuticals contribute to the health of people all over the world, and Daiichi Sankyo Vietnam has established internal systems to ensure a high level of safety management and regulatory affairs activities. It conducts ongoing training to make sure that each employee is aware of and adheres to the Company's safety policies. Daiichi Sankyo Vietnam exhaustively compiles safety management information (such as information on side effects) from around the world and provides accurate information on appropriate usage to medical professionals. Regulatory affairs acitivities ensure under compliance with relevant laws, local regulations and guidelines, as well as ethical and scientific aspects.
Provision of High-quality Information to Healthcare Professionals
Given that pharmaceuticals by nature have both benefits and risks that must be carefully balanced, it is important for pharmaceutical companies to generate high-quality information on their efficacy and safety, and to provide the information to the medical field in order to promote their proper use. In the early phase after the launch of a new drug, in particular, there is not a sufficient amount of information available to meet various needs in the medical practice, even though the efficacy and safety of the drug was confirmed in the development phase.
Through cooperation among relevant units, the Daiichi Sankyo Vietnam provided information relating to Pharmaceutical Products to healthcare professionals through medical journals, conference presentations, and proper use materials, the proper use of drugs is promoted with the aim of contributing to medical technology.
High-quality information is information created under compliance with laws and regulations which possesses medical and scientific value. Therefore, we check compliance with relevant laws, regulations and guidelines, as well as ethical and scientific aspects, when promoting pharmaceutical products.
Medical Affairs Division’s Activities
Since MA Unit launched a global MA structure in October 2017, a global medical plan for each product has been developed and activities related to creating and disseminating information based on the plan have been executed in globally with focus on the field of Oncology and the Specialty & Value Product.
Toward achieving the 2025 Vision, "MA unit strives to be a transformative strategic partner to deliver value-added medical solutions to enhance patient lives," the Unit works every day with the aim of being a partner who delivers optimal medical solutions to stakeholders who provide and receive healthcare, including healthcare professionals, patients, patients groups, etc. around the world, by maximizing the contribution in pharmaceutical treatment through activities to generate and disseminate highly valuable evidence for pharmaceutics that the Daiichi Sankyo Group delivers to the world.
In 2021, Daiichi Sankyo Vietnam launched Medical Affair function to handle prasugrel, edoxaban, methoxyflurane, edaranove, and other our value products for the generation and communication of accurate medical and scientific information externally and internally. Based on the study results, we will exchange medical and scientific information with external medical experts to identify clinical questions (questions of patients and people practicing medicine regarding the use of pharmaceuticals) and obtain new evidence by planning and promoting company-initiated study programs for investigating such questions. We will thus promote activities to create and disseminate information needed by patients and people practicing medicine.
